- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NPPA fixes retail price of 26 formulations; Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed prices of 26 formulations.
These include some popular drug brands and combination formulations like Telsartan Beta 25; Atocor Gold 10; Proxyfen Nano; GEMINOR M 3; Valera M 500; Dapagliflozin and Metformin Hydrochloride Extended-Release Tablet; Paracetamol and Mefenamic Acid Suspension and so on to treat various ailments.
Prominent drugmakers like Dr Reddy's Labs, Sun Pharma, Intas Pharma, Panacea Biotech, Mankind Pharma, Cipla, Abbott are involved in manufacturing the formulations mentioned in the list.
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Dapagliflozin + Metformin Hydrochloride Extended-Release Tablet | Each film-coated extended-release tablet contains: Dapagliflozin 10 mg, Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Micro Labs Ltd. | 40.44 |
2. | Dapagliflozin + Metformin Hydrochloride Extended Release Tablet | Each film-coated extended-release tablet contains: Dapagliflozin 10mg, Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Micro Labs Ltd. | 42.00 |
3. | Glimepiride Tablet | Each uncoated tablet contains: Glimepiride IP 3mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 8.38 |
4. | Glimepiride Tablet | Each uncoated tablet contains: Glimepiride IP 4mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 9.71 |
5. | Telmisartan + Metoprolol Succinate Extended Release Tablet (Telsartan Beta 25) | Each film coated tablet contains: Telmisartan IP 40mg, Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (As Extended Release Form) | 1 Tablet | M/s Akums Drugs and Pharmaceuticals Ltd. / Dr. Reddy's Laboratories Limited | 10.75 |
6. | Telmisartan + Metoprolol Succinate Extended Release Tablet (Telsartan Beta 50) | Each film coated bilayered tablet contains: Telmisartan IP 40mg, Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (As Extended Release Form) | 1 Tablet | M/s Akums Drugs and Pharmaceuticals Ltd. / Dr. Reddy's Laboratories Limited | 13.32 |
7. | Atorvastatin + Clopidogrel + Aspirin Capsule (Atocor Gold 10) | Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 10mg (As film coated tablet form), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet form), Aspirin IP 75mg (As enteric coated Tablet form) | 1 Capsule | M/s Akums Drugs & Pharmaceuticals Ltd. / Dr. Reddy's Laboratories Ltd. | 4.07 |
8. | Rabeprazole + Ondansetron Tablet | Each Enteric Coated tablet contains: Rabeprazole Sodium IP 20mg, | 1 Tablet | M/s SkymapPharmaceuticals Pvt. Ltd. / M/s German Remedies | 8.04 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Ondansetron Hydrochloride IP eq. to Ondansetron 4mg | Pharmaceuticals Pvt. Ltd. | ||||
9. | Nifedipine + Lidocaine Cream | Cream Contains: Nifedipine IP 0.30%w/w Lidocaine IP 1.50% w/w | 1 gram | M/s Om Sai Pharma Pack / M/s Zydus Healthcare Limited | 4.79 |
10. | Cefixime + Ofloxacin Dispersible Tablet | Each uncoated dispersible tablet contains: Cefixime IP (as trihydrate) eq. to Anhydrous Cefixime 200mg Ofloxacin IP 200mg | 1 Tablet | M/s Windlas Biotech Pvt. Ltd. / M/s Intas Pharmaceuticals Limited | 11.28 |
11. | Desvenlafaxine (Extended Release) + Clonazepam Tablet | Each uncoated Bilayered tablet contains: Desvenlafaxine Succinate USP eq. to Desvenlafaxine 100mg (As Extended Release Form) Clonazepam IP 0.5mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Intas Pharmaceuticals Limited | 20.38 |
12. | Diclofenac + Virgin Linseed oil + Methyl salicylate + Menthol Gel (Proxyfen Nano) | Gel contains: Diclofenac Diethylamine IP1.16% w/w (equivalent to Diclofenac sodium 1% w/w). Virgin Linseed oil BP 3.0% w/w (Containing Predominantly Alpha Linolenic acid), Methyl salicylate 10% w/w, Menthol IP 5% w/w, | 1 Gram | M/s Akums Drugs & Pharmaceuticals Ltd. /M/s Wockhardt Limited | 2.69 |
13. | Norethisterone Acetate Controlled Release Tablet | Each film coated controlled released tablet contains: Norethisterone Acetate BP 15mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Limited | 18.00 |
14. | Metformin Hydrochloride(Prolonged release) + Glimepiride Tablet (GEMINOR M 3) | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (As Prolonged Release form), Glimepiride IP 3mg | 1 Tablet | M/s Macleods Pharmaceuticals Limited | 8.00 |
15. | Metformin Hydrochloride (Prolonged release)+ Glimepiride Tablet (GEMINOR M4) | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (As Prolonged Release form), Glimepiride IP 4mg | 1 Tablet | M/s Macleods Pharmaceuticals Limited | 9.83 |
16. | Telmisartan + Cilnidipine Tablet (TELMIDUCE CL) | Each film coated Tablet contains: Telmisartan IP 40mg, Cilnidipine IP 10mg, | 1 Tablet | M/s Macleods Pharmaceuticals Limited | 8.94 |
17. | Telmisartan + Cilnidipine + Chlorthalidone Tablet (NEXOVAS TC) | Each Film Coated Tablet contains: Cilnidipine IP 10mg, Telmisartan IP 40mg, Chlorthalidone IP 12.5mg | 1 Tablet | M/s Macleods Pharmaceuticals Limited | 12.16 |
18. | Levetiracetam + Sodium Chloride Infusion (Levenue RTU 500) | Each 100ml contains: Levetiracetam IP 500mg Sodium Chloride IP 820mg | per 100 ml pack | M/s Akums Drugs & Pharmaceuticals Limited / M/s Alkem Laboratories Ltd. | 91.56 |
19. | Levetiracetam + Sodium Chloride Infusion (Levenue RTU 1000) | Each 100ml contains: Levetiracetam IP 1000mg Sodium Chloride IP 750mg | per 100 ml pack | M/s Akums Drugs & Pharmaceuticals Limited / M/s Alkem Laboratories Ltd. | 148.72 |
20. | Paracetamol + Mefenamic Acid Suspension | Each 5ml contains: Paracetamol IP 250mg, Mefenamic Acid IP 100mg | 1 ml | M/s Tirupati Medicare Ltd. / M/s Cipla Limited | 0.67 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
21. | Camylofin Dihydrochloride + Paracetamol tablet | Each film coated tablet contains: Camylofin Dihydrochloride 50 mg Paracetamol IP 325 mg | 1 Tablet | M/s Khandelwal Laboratories Pvt. Ltd./ M/s Abbott Healthcare Pvt. Ltd. | 4.93 |
22. | Glimepiride +Voglibose + Metformin HCL (extended Release) Tablet (GEMER V 1) | Each uncoated bilayer tablet contains: Glimepiride IP 1 mg , Voglibose IP 0.2 mg , Metformin Hydrochloride IP 500 mg (as extended release form) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Sun Pharma Laboratories Ltd. | 9.54 |
23. | Pantoprazole Gastro Resistant tablet | Each Gastro resistant tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 40 mg | 1 Tablet | M/s Panacea Biotech Pharma Ltd. | 5.80 |
24. | Telmisartan + Chlorthalidone + Cilnidipine Tablet | Each film coated tablet contains: Telmisartan IP 40 mg, Cilnidipine IP 10 mg , Chlorthalidone IP 12.5 mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd./ M/s Mankind Pharma Ltd. | 12.28 |
25. | Human Prothrombin Complex IP 250IU | Each vial contains: Human Coagulation Factor II 175-412 IU Human Coagulation Factor VII 40-260 IU Human Coagulation Factor IX 250 IU Human Coagulation Factor X 150-530 IU Protein C 230 – 450IU Protein S 220 – 440IU Heparin 15 – 30 IU Total Protein Not More than 52 g/l | Per vial | M/s Intas Pharmaceuticals Limited | 19819.49 |
26. | Evogliptin + Metformin Hydrochloride Sustained release Tablet (Valera M 500) | Each film-coated bilayer tablet contains: Evogliptin Tartrate eq. to Evogliptin 5mg, Metformin Hydrochloride IP 500mg (As sustained release form) | 1 Tablet | M/s Alkem Healthscience/ M/s Alkem Laboratories Ltd. | 17.11 |
(a) The manufacturer of the above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS, and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
To access the official notification, click on the link below-
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751